📊 EVFM Key Takeaways
Is EVFM a Good Investment? Thesis Analysis
Evofem Biosciences exhibits severe financial distress with negative stockholders' equity of -$74.3M, indicating the company is technically insolvent. Despite modest revenue growth of 4.2% YoY and a 16.7% operating margin, negative operating cash flow of -$2.0M and critically low liquidity (0.18x current ratio) with only $578K in cash create an imminent solvency crisis. The company's ability to continue operations is highly questionable without immediate capital restructuring or substantial external financing.
Why Buy EVFM? Key Strengths
- Positive net income of $391K with 42.7% YoY improvement showing path to profitability
- Modest revenue growth of 4.2% YoY indicating stable top-line performance
- Relatively strong operating margin of 16.7% demonstrating operational efficiency
EVFM Investment Risks to Consider
- Negative stockholders' equity of -$74.3M indicating technical insolvency and balance sheet distress
- Critical liquidity crisis with current ratio of 0.18x and only $578K cash against $89.7M total liabilities
- Severely negative operating cash flow of -$2.0M suggesting the company is burning cash and cannot sustain operations without external funding
- Negative free cash flow of -$2.0M with -9.9% FCF margin indicating unsustainable business model
- High leverage with $2.8M long-term debt and weak interest coverage of 1.4x
- Zero insider Form 4 filings in last 90 days indicating lack of insider confidence
Key Metrics to Watch
- Operating cash flow trajectory and path to positive free cash flow
- Cash balance and runway given current burn rate
- Stockholders' equity recovery and balance sheet restructuring efforts
- Revenue growth acceleration beyond 4.2% to support profitability scaling
EVFM Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
EVFM Profitability Ratios
EVFM vs Healthcare Sector
How Evofem Biosciences, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is EVFM Overvalued or Undervalued?
Based on fundamental analysis, Evofem Biosciences, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
EVFM Balance Sheet & Liquidity
EVFM 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Evofem Biosciences, Inc.'s revenue has grown significantly by 11% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.11 indicates the company is currently unprofitable.
EVFM Growth Metrics (YoY)
EVFM Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $4.5M | $956.0K | $-0.01 |
| Q2 2025 | $4.2M | -$828.0K | $0.00 |
| Q1 2025 | $845.0K | $956.0K | $0.00 |
| Q3 2024 | $4.5M | $1.4M | $-0.02 |
| Q2 2024 | $2.5M | $1.4M | $0.00 |
| Q1 2024 | $3.6M | -$2.4M | $-0.16 |
| Q3 2023 | $5.1M | -$2.4M | $0.09 |
| Q2 2023 | $2.5M | -$2.4M | $-5.43 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
EVFM Capital Allocation
EVFM SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Evofem Biosciences, Inc. (CIK: 0001618835)
📋 Recent SEC Filings
❓ Frequently Asked Questions about EVFM
What is the AI rating for EVFM?
Evofem Biosciences, Inc. (EVFM) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are EVFM's key strengths?
Claude: Positive net income of $391K with 42.7% YoY improvement showing path to profitability. Modest revenue growth of 4.2% YoY indicating stable top-line performance.
What are the risks of investing in EVFM?
Claude: Negative stockholders' equity of -$74.3M indicating technical insolvency and balance sheet distress. Critical liquidity crisis with current ratio of 0.18x and only $578K cash against $89.7M total liabilities.
What is EVFM's revenue and growth?
Evofem Biosciences, Inc. reported revenue of $20.2M.
Does EVFM pay dividends?
Evofem Biosciences, Inc. pays dividends, with $0.2M distributed to shareholders in the trailing twelve months.
Where can I find EVFM SEC filings?
Official SEC filings for Evofem Biosciences, Inc. (CIK: 0001618835) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is EVFM's EPS?
Evofem Biosciences, Inc. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is EVFM a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, Evofem Biosciences, Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is EVFM stock overvalued or undervalued?
Valuation metrics for EVFM: ROE of N/A (sector avg: 15%), net margin of 1.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy EVFM stock in 2026?
Our dual AI analysis gives Evofem Biosciences, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is EVFM's free cash flow?
Evofem Biosciences, Inc.'s operating cash flow is $-2.0M, with capital expenditures of $5.0K. FCF margin is -9.9%.
How does EVFM compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 1.9% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.18 (avg: 2).